A Multi-center, Open-label, Dose-escalation Study in Patients With Advanced Cacner to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Total ASA404.

Trial Profile

A Multi-center, Open-label, Dose-escalation Study in Patients With Advanced Cacner to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Total ASA404.

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Apr 2014

At a glance

  • Drugs Vadimezan (Primary) ; Carboplatin; Docetaxel; Paclitaxel
  • Indications Solid tumours
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 01 Aug 2011 Actual initiation date (Dec 2010) added as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Planned end date changed from Jan 2011 to Dec 2010 as reported by ClinicalTrials.gov.
    • 01 Aug 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top